Dr. Wang joined in BeiGene’s early days, in 2011. Currently the Global Head of R&D, his previous roles in the company have included heading the Discovery Biomarkers, In Vivo Pharmacology groups and Clinical Biomarkers, and Translational Research. He was appointed as head of China Development in 2016, responsible for clinical development in the Asia-Pacific region. In 2019, he took on more responsibilities including global research, global clinical operation, and global biometrics.

Prior to joining BeiGene, Dr. Wang was the director of research at Joyant Pharmaceuticals, a biotech company based in Dallas, Texas.

Dr. Wang received his B.S. in 1996 from Fudan University and Ph.D. in 2001 from the University of Texas Health Science Center at San Antonio. He completed his post-doc training with Dr. Xiaodong Wang at Howard Hughes Medical Institute.